Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	32.36 (5)
Ask (Size)	32.49 (100)
Prev. Close	32.48
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	84,677,939
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 3/21

March 21, 2024

Via Investor Brand Network

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production ↗

March 15, 2024

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...

Via Benzinga

Performance

More News

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2024

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)

February 29, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/21

February 21, 2024

Via Investor Brand Network

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/13

February 13, 2024

Via Investor Brand Network

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 1/25

January 25, 2024

Via Investor Brand Network

CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY

February 16, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

Via MarketBeat

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst ↗

February 13, 2024

Via Benzinga

Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high ↗

February 13, 2024

Via Benzinga

6 Analysts Have This to Say About CymaBay Therapeutics ↗

December 15, 2023

Via Benzinga

Recap: CymaBay Therapeutics Q3 Earnings ↗

November 07, 2023

Via Benzinga

Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B ↗

February 12, 2024

Via Benzinga

Dow Up Triple Digits, Hits Fresh Highs ↗

February 12, 2024

Via Talk Markets

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)

February 12, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Why is CymaBay (CBAY) Stock Up 25% Today? ↗

February 12, 2024

Via InvestorPlace

CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗

February 12, 2024

Via Benzinga

Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics ↗

February 12, 2024

Via Benzinga

CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders

February 12, 2024

From Halper Sadeh LLC

Via Business Wire

Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B ↗

February 12, 2024

Via Benzinga

CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition ↗

February 12, 2024

Via Investor's Business Daily

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

February 12, 2024

From Gilead Sciences, Inc.

Via Business Wire

Why CymaBay Morphed From Dollar Stock To Biotech Rocket ↗

December 28, 2023

Via Investor's Business Daily

Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know ↗

November 08, 2023

Via Benzinga

Frequently Asked Questions

Is CymaBay Therapeutics Inc. - Common Stock publicly traded?

Yes, CymaBay Therapeutics Inc. - Common Stock is publicly traded.

What exchange does CymaBay Therapeutics Inc. - Common Stock trade on?

CymaBay Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for CymaBay Therapeutics Inc. - Common Stock?

The ticker symbol for CymaBay Therapeutics Inc. - Common Stock is CBAY on the Nasdaq Stock Market

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.